EP1871769
CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
14.12.2005EP published:
22.2.2017EP application number:
05818127.2
EPO information:
European Patent Register
Max expiry date:
13.12.2025
Title:
CRYSTALLINE FORMS OF THE COMPOUND 4-(6-CHLORO-2,3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE.
Timeline
Today
14.12.2005EP application
22.2.2017EP Publication
Owner
Name:
AstraZeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
FORD, James GairAstraZenecaAddress:
MacclesfieldCheshire SK10 2NA, GB
Name:
MCCABE, James FrancisAstraZenecaAddress:
MacclesfieldCheshire SK10 2NA, GB
Name:
O'KEARNEY-MCMULLAN, AnneAstraZenecaAddress:
MacclesfieldCheshire SK10 2NA, GB
Name:
O'KEEFE, PhilipAstraZeneca R & D CharnwoodAddress:
LoughboroughLeicestershire LE11 5RH, GB
Name:
POINTON, Simon MarkAstraZenecaAddress:
Maccl esfieldCheshire SK10 2NA, GB
Name:
POWELL, LynAstraZenecaAddress:
MacclesfieldCheshire SK10 2NA, GB
Name:
PURDIE, MarkAstraZeneca R & D CharnwoodAddress:
LoughboroughLeicestershire LE11 5RH, GB
Name:
WITHNALL, JaneAstraZeneca R & D CharnwoodAddress:
LoughboroughLeicestershire LE11 5RH, GB
Priority
Number:
0427697Date:
17.12.2004Country:
GB
Classification
Categories:
C07D 405/12, A61K 31/517